Publication

New Avenues for Optimal Treatment of Atrial Fibrillation and Stroke Prevention.

Journal Paper/Review - Feb 25, 2021

Units
PubMed
Doi
Contact

Citation
De Marchis G, Sposato L, Kühne M, Dittrich T, Bonati L, Fischer U, Chaturvedi S. New Avenues for Optimal Treatment of Atrial Fibrillation and Stroke Prevention. Stroke 2021; 52:1490-1499.
Type
Journal Paper/Review (English)
Journal
Stroke 2021; 52
Publication Date
Feb 25, 2021
Issn Electronic
1524-4628
Pages
1490-1499
Brief description/objective

One in 3 individuals free of atrial fibrillation (AF) at index age 55 years is estimated to develop AF later in life. AF increases not only the risk of ischemic stroke but also of dementia, even in stroke-free patients. In this review, we address recent advances in the heart-brain interaction with focus on AF. Issues discussed are (1) the timing of direct oral anticoagulants start following an ischemic stroke; (2) the comparison of direct oral anticoagulants versus vitamin K antagonists in early secondary stroke prevention; (3) harms of bridging with heparin before direct oral anticoagulants; (4) importance of appropriate direct oral anticoagulants dosing; (5) screening for AF in high-risk populations, including the role of wearables; (6) left atrial appendage occlusion as an alternative to oral anticoagulation; (7) the role of early rhythm-control therapy; (8) effect of lifestyle interventions on AF; (9) AF as a risk factor for dementia. An interdisciplinary approach seems appropriate to address the complex challenges posed by AF.